Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial

INDIANAPOLIS , Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared